Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Hypertension (chronic stable angina is not an approved indication in the US; however, it is used off-label for short-term treatment of hypertension in hospitalized patients and for subarachnoid hemorrhage to prevent vasospasm.,Off-label: short-term management of hypertension in hospitalized patients, prevention of cerebral vasospasm after subarachnoid hemorrhage.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
20-40 mg orally three times daily.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Hepatic metabolism primarily via cytochrome P450 isoenzymes CYP3A4 and CYP2C8, with minor contributions from CYP2D6.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
>95% bound to albumin and alpha-1 acid glycoprotein
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
0.6-1.2 L/kg (large Vd due to extensive tissue binding)
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral: 35-60% (first-pass metabolism; increased with hepatic disease)
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
For GFR < 30 m L/min: initiate at 20 mg orally twice daily.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Child-Pugh class B or C: reduce dose by 50% and titrate slowly.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Not established; safety and efficacy not determined.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Initiate at 20 mg orally twice daily; titrate cautiously.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
No FDA black box warning.
None
Hypotension (especially in patients with ventricular dysfunction or those receiving beta-blockers), increased angina (rare, more common with dihydropyridines), peripheral edema, congestive heart failure (use caution in patients with severe left ventricular dysfunction), hepatic impairment (reduce dose), renal impairment (monitor blood pressure), abrupt discontinuation may cause angina exacerbation.
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Hypersensitivity to nicardipine or any dihydropyridine, advanced aortic stenosis (may reduce coronary perfusion), second- or third-degree AV block (unless paced), sick sinus syndrome (unless paced), cardiogenic shock, concomitant use with strong CYP3A4 inducers (e.g., rifampin) due to decreased efficacy.
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Grapefruit and grapefruit juice increase nicardipine exposure and should be avoided. High-fat meals may reduce absorption; take consistently with or without food. Alcohol may enhance hypotensive effects.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Cardene (nicardipine) is classified as FDA Pregnancy Category C. In animal studies, nicardipine was associated with embryotoxicity, fetotoxicity, and teratogenicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use in the first trimester should be avoided if possible; in the second and third trimesters, potential benefits must outweigh risks, particularly due to possible maternal hypotension and fetal hypoxia.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Nicardipine is excreted in human breast milk. The M/P ratio is approximately 0.7. Limited data suggest that concentrations in breast milk are low relative to therapeutic doses, but the effects on the nursing infant are unknown. Caution is advised.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Pregnancy may alter the pharmacokinetics of nicardipine due to increased plasma volume and altered hepatic metabolism. However, specific dose adjustment recommendations are not established. In hypertensive emergencies, intravenous nicardipine is often used at standard doses with careful titration to avoid maternal hypotension. Oral doses may require titration based on response, starting at 20 mg three times daily.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
CARDENE (nicardipine) is a dihydropyridine calcium channel blocker used intravenously for acute hypertension. Onset is rapid (1-2 minutes), making it ideal for hypertensive emergencies. It is metabolized hepatically; reduce dose in hepatic impairment. Does not cause reflex tachycardia as prominently as other dihydropyridines. Contraindicated in advanced aortic stenosis. Can be used for hypertension during pregnancy but with caution.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Take exactly as prescribed; do not stop abruptly.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Report irregular heartbeat, shortness of breath, or swelling of the ankles or feet.,Keep all appointments for blood pressure monitoring.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE vs ADALAT, answered by our medical review team.
CARDENE is a Calcium Channel Blocker that works by Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE and ADALAT depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE is: 20-40 mg orally three times daily.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE is classified as Category C. Cardene (nicardipine) is classified as FDA Pregnancy Category C. In animal studies, nicardipine was associated with embryotoxicity, fetotoxicity, and teratogenicity at high doses. . ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.